Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.33 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5205626 | 0.83 | KDR (0.60) | KDRMAPK8MAPK10MAPK14ALK | |
| SCHEMBL5212977 | 0.83 | KDR (0.46) | KDRFGFR1MAPK8MAPK10MAPK14 | |
| SCHEMBL5210216 | 0.82 | KDR (0.49) | KDRFGFR1MAPK8MAPK10MAPK14 | |
| SCHEMBL5211166 | 0.81 | MAPK8 (0.45) | KDRFGFR1MAPK8MAPK10MAPK14 | |
| SCHEMBL5206506 | 0.80 | KDM4E (0.31) | KDRMT-CO2 | |
| SCHEMBL5210224 | 0.79 | KDR (0.69) | KDRFGFR1MAPK8MAPK10MAPK14 | |
| SCHEMBL5210220 | 0.79 | KDR (0.69) | KDRFGFR1MAPK8MAPK10MAPK14 | |
| SCHEMBL5210372 | 0.79 | KDR (0.46) | KDRMAPK8MAPK10MAPK14ALK | |
| SCHEMBL5241880 | 0.78 | KDR (0.62) | KDRFGFR1MAPK8MAPK10MAPK14 | |
| SCHEMBL5241886 | 0.78 | KDR (0.62) | KDRFGFR1MAPK8MAPK10MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585743-B1 | 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES | PFIZER (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060160858-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS INC. | 2006-07-20 | — | — | US | disclosed |
| US-7053107-B2 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040192735-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192735-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, CNKSR1 | KDR 88/4885FGFR1 315/4885MAPK8 257/4885 |
| US-20060160858-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, CNKSR1 | KDR 88/4885FGFR1 315/4885MAPK8 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.